단백질체학 시장 : 유형, 제품 유형, 샘플 유형, 자동화 레벨, 용도, 최종 사용자별 - 세계 시장 예측(2026-2032년)

The Proteomics Market is projected to grow by USD 100.72 billion at a CAGR of 14.07% by 2032.

Proteomics Executive Summary

Proteomics is moving from discovery science into a core engine for precision medicine, biopharmaceutical R&D, diagnostics, food safety, and environmental testing. By measuring proteins, post-translational modifications, protein abundance, and protein interactions, proteomics provides functional biological insight that genomics alone cannot deliver.

Demand is supported by sustained public and private investment in life sciences, wider use of high-resolution mass spectrometry, expansion of biobanks, and adoption of high-throughput affinity platforms. For industry leaders, the proteomics market is increasingly defined by rising sample throughput, deeper proteome coverage, improved reproducibility, and growing demand for clinically relevant biomarker evidence.

Transformative Shifts in the Proteomics Landscape

The proteomics landscape is being reshaped by next-generation mass spectrometry, data-independent acquisition, single-cell proteomics, spatial proteomics, and high-multiplex affinity assays. These technologies are improving sensitivity, quantitative precision, and sample efficiency, enabling researchers to profile low-abundance proteins and complex disease pathways at scale.

At the same time, cloud computing, open repositories such as ProteomeXchange and PRIDE, and standardized quality-control practices are improving data comparability and research transparency. The competitive focus is shifting from isolated instruments toward integrated workflows that combine sample preparation, analytics software, automation, quality control, and validated biological interpretation.

Cumulative Impact of Artificial Intelligence on Proteomics

Artificial intelligence is accelerating proteomics by improving peptide identification, spectral prediction, protein structure modeling, biomarker prioritization, and multi-omics integration. AI-enabled protein structure advances have strengthened confidence in structural biology, while machine learning supports faster interpretation of high-dimensional mass spectrometry and affinity-based datasets.

The cumulative impact is operational as well as scientific. AI-enabled workflows can reduce manual curation, detect batch effects, improve assay reproducibility, support missing-value handling, and accelerate hypothesis generation across oncology, immunology, neurology, cardiometabolic disease, rare disease, and infectious disease research. Governance remains essential because model performance depends on data quality, cohort diversity, traceable metadata, and transparent validation.

Key Regional Insights for Proteomics

North America remains a leading proteomics hub due to strong publicly funded biomedical research, large pharmaceutical R&D pipelines, advanced clinical laboratory infrastructure, and early adoption of high-resolution mass spectrometry and automated sample preparation. Europe benefits from established research infrastructure, coordinated science funding, regulatory expertise, biobank networks, and strong academic-industry collaboration across Germany, France, Italy, Spain, and the United Kingdom.

Asia-Pacific is expanding quickly as China, Japan, South Korea, India, Singapore, and Australia invest in genomics, biomanufacturing, clinical research, precision medicine, and advanced analytical technologies. Latin America is gaining relevance through Brazil and Mexico's growing academic, hospital, and public health research networks. The Middle East is investing in national health transformation, genomics, biobanking, and tertiary care modernization, while Africa's long-term opportunity is tied to infectious disease research, population diversity, newborn and maternal health studies, and laboratory capacity building.

Key Group Insights Across Global Proteomics Markets

ASEAN proteomics growth is supported by Singapore's biomedical ecosystem, Thailand's clinical research base, Malaysia's healthcare infrastructure, and expanding diagnostics demand across Southeast Asia. The GCC is prioritizing precision health, national biobanks, genomic medicine, and healthcare diversification, creating demand for proteomics platforms that support population-scale disease risk assessment and translational research.

The European Union strengthens proteomics through cross-border research funding, regulatory harmonization, data protection frameworks, and collaborative research networks that shape clinical adoption. BRICS countries offer scale, disease-burden diversity, public health research needs, and manufacturing potential. G7 countries lead in premium instrumentation, pharmaceutical partnerships, clinical translation, and advanced academic research, while NATO members benefit from strong biomedical security, biodefense readiness, infectious disease surveillance, and resilient health research systems.

Key Country Insights in Proteomics

The United States leads in proteomics innovation through public biomedical funding, biotechnology clusters, pharmaceutical R&D, advanced clinical laboratory infrastructure, and extensive clinical trial activity. Canada supports growth through strong academic networks, population health research, and national research programs, while Mexico and Brazil are strengthening clinical research capacity, hospital-based studies, and regional diagnostics access.

In Europe, the United Kingdom, Germany, France, Italy, and Spain combine academic excellence with pharmaceutical research, hospital-based translational medicine, biobanking, and clinical proteomics expertise. Russia retains scientific capability in analytical chemistry and biomedical research but faces constraints linked to sanctions, procurement complexity, and technology access. China is scaling biomedical research, clinical studies, and instrument adoption rapidly; India is expanding contract research, biopharma, and diagnostics capabilities; Japan and South Korea remain strong in precision technology, automation, and translational research; and Australia contributes through genomics, oncology, population health, and well-established clinical research programs.

Actionable Recommendations for Industry Leaders

Industry leaders should prioritize workflow integration, assay reproducibility, data quality, and clinical evidence generation rather than competing on instrument specifications alone. Partnerships with hospitals, biobanks, contract research organizations, academic medical centers, and pharmaceutical developers can accelerate validation and improve access to diverse cohorts.

Organizations should invest in AI-ready data architecture, standardized sample handling, interoperable software, reference materials, and regulatory-grade documentation. Commercial success will depend on proving analytical validity, clinical utility, operational efficiency, and scalability across discovery research, translational medicine, regulated diagnostics, and population health applications.

Research Methodology

This executive summary is grounded in secondary research from publicly available, authoritative sources, including government science agencies, regulatory bodies, peer-reviewed literature, clinical trial registries, standards organizations, and recognized proteomics data repositories. Market interpretation emphasizes verifiable technology adoption patterns, funding signals, infrastructure development, research output, and regulatory direction.

The methodology combines technology trend analysis, regional policy review, ecosystem assessment, and application mapping across pharmaceutical research, diagnostics, academia, public health, and contract research. Insights are normalized to avoid unsupported forecasts and to focus on evidence-based drivers shaping the proteomics industry.

Conclusion

Proteomics is becoming indispensable to precision medicine because proteins represent the dynamic biology that drives disease progression, treatment response, drug resistance, and therapeutic opportunity. Advances in mass spectrometry, affinity assays, automation, spatial biology, single-cell analysis, and AI are making protein measurement faster, deeper, and more scalable.

The strongest opportunities will emerge where scientific performance is paired with clinical validation, data governance, interoperability, and globally scalable workflows. Organizations that connect proteomic discovery with actionable diagnostics, drug development decisions, and population health programs will be best positioned for durable industry relevance.

Table of Contents

1. Preface

• 1.1. Objectives of the Study
• 1.2. Market Definition
• 1.3. Market Segmentation & Coverage
• 1.4. Years Considered for the Study
• 1.5. Currency Considered for the Study
• 1.6. Language Considered for the Study
• 1.7. Key Stakeholders

2. Research Methodology

• 2.1. Introduction
• 2.2. Research Design
  • 2.2.1. Primary Research
  • 2.2.2. Secondary Research
• 2.3. Research Framework
  • 2.3.1. Qualitative Analysis
  • 2.3.2. Quantitative Analysis
• 2.4. Market Size Estimation
  • 2.4.1. Top-Down Approach
  • 2.4.2. Bottom-Up Approach
• 2.5. Data Triangulation
• 2.6. Research Outcomes
• 2.7. Research Assumptions
• 2.8. Research Limitations

3. Executive Summary

• 3.1. Introduction
• 3.2. CXO Perspective
• 3.3. Market Size & Growth Trends
• 3.4. Market Share Analysis, 2025
• 3.5. FPNV Positioning Matrix, 2025
• 3.6. New Revenue Opportunities
• 3.7. Next-Generation Business Models
• 3.8. Industry Roadmap

4. Market Overview

• 4.1. Introduction
• 4.2. Industry Ecosystem & Value Chain Analysis
  • 4.2.1. Supply-Side Analysis
  • 4.2.2. Demand-Side Analysis
  • 4.2.3. Stakeholder Analysis
• 4.3. Market Dynamics
  • 4.3.1. Key Drivers
  • 4.3.2. Key Restraints
  • 4.3.3. Key Opportunities
  • 4.3.4. Key Challenges
• 4.4. Porter's Five Forces Analysis
• 4.5. PESTLE Analysis
• 4.6. Market Outlook
  • 4.6.1. Near-Term Market Outlook (0-2 Years)
  • 4.6.2. Medium-Term Market Outlook (3-5 Years)
  • 4.6.3. Long-Term Market Outlook (5-10 Years)
• 4.7. Go-to-Market Strategy

5. Market Insights

• 5.1. Consumer Insights & End-User Perspective
• 5.2. Consumer Experience Benchmarking
• 5.3. Opportunity Mapping
• 5.4. Distribution Channel Analysis
• 5.5. Pricing Trend Analysis
• 5.6. Regulatory Compliance & Standards Framework
• 5.7. ESG & Sustainability Analysis
• 5.8. Disruption & Risk Scenarios
• 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of Artificial Intelligence 2026

7. Proteomics Market, by Type

• 7.1. Expression Proteomics
• 7.2. Functional Proteomics
• 7.3. Structural Proteomics

8. Proteomics Market, by Product Type

• 8.1. Consumables
  • 8.1.1. Antibody Kits
  • 8.1.2. Columns
  • 8.1.3. Microarrays
  • 8.1.4. Reagents
    • 8.1.4.1. Chemicals
    • 8.1.4.2. Enzymes
• 8.2. Instruments
  • 8.2.1. Chromatography Systems
  • 8.2.2. Electrophoresis Systems
  • 8.2.3. Mass Spectrometers
  • 8.2.4. Microarray Scanners
  • 8.2.5. Protein Fractionation Units
• 8.3. Service Offerings
  • 8.3.1. Custom Antibody Development
  • 8.3.2. Protein Identification & Quantification Services
  • 8.3.3. Protein Separation & Purification Services
• 8.4. Software Solutions
  • 8.4.1. Bioinformatics Platforms
  • 8.4.2. Cloud Based Services
  • 8.4.3. Data Analysis Tools
    • 8.4.3.1. Pathway Analysis
    • 8.4.3.2. Protein Identification
    • 8.4.3.3. Quantitative Analysis

9. Proteomics Market, by Sample Type

• 9.1. Blood
• 9.2. Tissue
• 9.3. Urine
• 9.4. Cell Culture
• 9.5. Saliva

10. Proteomics Market, by Automation Level

• 10.1. Manual Workflow
• 10.2. Semi-Automated Workflow
• 10.3. Fully Automated Workflow

11. Proteomics Market, by Application

• 11.1. Agricultural Research
• 11.2. Biomarker Discovery
• 11.3. Clinical Diagnostics
  • 11.3.1. Cancer Proteomics
  • 11.3.2. Cardiovascular Disease
  • 11.3.3. Infectious Disease Testing
  • 11.3.4. Neurological Disorders
• 11.4. Disease Diagnostics
• 11.5. Drug Discovery
• 11.6. Environmental Monitoring
• 11.7. Food Safety Testing

12. Proteomics Market, by End-User

• 12.1. Academic Research Institutions
• 12.2. Contract Research Organizations
• 12.3. Hospitals & Diagnostic Labs
• 12.4. Pharmaceuticals & Biotechnology Companies

13. Proteomics Market, by Region

• 13.1. Asia-Pacific
• 13.2. North America
• 13.3. Latin America
• 13.4. Europe
• 13.5. Middle East
• 13.6. Africa

14. Proteomics Market, by Group

• 14.1. ASEAN
• 14.2. GCC
• 14.3. European Union
• 14.4. BRICS
• 14.5. G7
• 14.6. NATO

15. Proteomics Market, by Country

• 15.1. United States
• 15.2. Canada
• 15.3. Mexico
• 15.4. Brazil
• 15.5. United Kingdom
• 15.6. Germany
• 15.7. France
• 15.8. Russia
• 15.9. Italy
• 15.10. Spain
• 15.11. China
• 15.12. India
• 15.13. Japan
• 15.14. Australia
• 15.15. South Korea

16. Competitive Landscape

• 16.1. Market Concentration Analysis, 2025
  • 16.1.1. Concentration Ratio (CR)
  • 16.1.2. Herfindahl Hirschman Index (HHI)
• 16.2. Recent Developments & Impact Analysis, 2025
• 16.3. Product Portfolio Analysis, 2025
• 16.4. Benchmarking Analysis, 2025

17. Company Profiles

• 17.1. Agilent Technologies, Inc.
• 17.2. Alphalyse A/S
• 17.3. Applied Biomics, Inc.
• 17.4. BGI Group
• 17.5. Bio-Rad Laboratories, Inc.
• 17.6. Biogenity ApS
• 17.7. Bruker Corporation
• 17.8. CD Genomics
• 17.9. CovalX AG
• 17.10. Creative Proteomics
• 17.11. Danaher Corporation
• 17.12. Evosep ApS
• 17.13. Illumina, Inc.
• 17.14. JPT Peptide Technologies GmbH
• 17.15. Merck KGaA
• 17.16. Metware Biotechnology Inc.
• 17.17. MS Bioworks LLC
• 17.18. PerkinElmer Inc.
• 17.19. PolyQuant GmbH
• 17.20. Proteome Factory AG
• 17.21. Proteomics International Pty Ltd.
• 17.22. Rapid Novor Inc.
• 17.23. Thermo Fisher Scientific Inc
• 17.24. VProteomics
• 17.25. Waters Corporation